PNPLA3 I148M and TM6SF2 E167K variants were tightly correlated with the decreased risk of CHD in NAFLD patients and the decreased serum lipid levels in overall series along with the increased numbers of risk alleles. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.